Robotic Radiosurgical Stereotactic Body Radiation Therapy for Liver Metastases

Abstract

Results: Transcatheter arterial chemoembolization (TACE) combined with EBRT constitutes an improved therapeutic strategy for unresectable but confined intrahepatic HCC. We found that EBRT can improve survival of HCC patients with PV tumor thrombi, and decreases the mortality of HCC patients with abdominal LNM, prolonging median survival to 8.4 months. EBRT also shrinks adrenal and lung metastatic HCC lesions, resulting in median survival times of 13.6 and 13.4 months, respectively. For patients with bone metastases from HCC, EBRT significantly relieved the symptoms, although median survival time for these patients was 7.4 months. EBRT is effective for treatment of intermediate/advanced stages of HCC. Although our finding is based only on retrospective analysis, no therapeutic option that provides better treatment than EBRT in this indication has thus far been identified. Because sorafenib has been recommended as a treatment strategy by the NCCN for HCC, we compared the survival after EBRT with sorafenib treatment on the basis of published clinical data in the Table and found that EBRT was more effective than sorafenib for improving patient survival when tested on tumors of comparable metastatic size. Conclusion: EBRT should be included in the NCCN guideline as a treatment strategy for intermediate/advanced HCC. Author Disclosure: Z. Zeng: None.